Thursday, August 28, 2025

Antibe: Canaccord Raises Price Target After Q4 Results

On June 28th,  Antibe Therapeutics (TSX: ATE) reported their fourth quarter and year-end financials. The company announced full-year revenue of $9.7 million, which came in flat year over year, with a larger than expected net loss of $26.3 million. The company ended the year with $72 million in cash.

The company has seven analysts covering it, with a weighted 12-month price target of C$14.55, or an almost 300% upside. Out of the seven analysts, one has a strong buy rating while the other six have buy ratings. The street high comes from Brookline Capital with a C$20.60 price target and the lowest sits at C$7.00 from Raymond James.

Canaccord Genuity raised its 12-month price target to C$15.00, up from C$14.50, while reiterating their speculative buy rating. Tania Gonsalves, Canaccord’s analyst, says that the company left 2021, “well-capitalized and de-risked.”

For the fourth quarter and full-year results, Gonsalves says that there were no real deviations into the results and they came generally in line with their expectations. For the fourth quarter, Citegenix revenue came in slightly higher at $3 million versus their $2.6 million estimate. Meanwhile R&D expenses came in slightly higher at $3.1 million versus their $2.5 million estimate. She adds, “as a clinical stage biotechnology company, quarterly financials are not a materially impactful event.”

The most important thing she says is after the two raises the company has $72 million in cash, which by their estimates “will be sufficient to fund operations for over two years, including otenaproxesul’s full ~$60.0M adaptive Phase 2/3 program.” She then refers to this quarter as a very productive de-risking quarter for the company.

Gonsalves says that the collaboration with Dalriade will help drive pipeline expansion. The team at Dalriada has 50 scientists and specializes in developing small-molecule drugs. She says it will help “Accelerate screening, selection, and advancement of drug candidates for IND-enabling studies.”

Below you can see Canaccord’s changes to estimates, which were used to get to the new price target.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Nord Precious Metals Identifies 29 Veins At Castle East Following 3D Modeling

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

Related News

Stifel Releases Third Quarter Earning Preview For US Multi State Operators

Last week Stifel released their Q3 earnings preview for all the MSO’s while stating that...

Sunday, November 1, 2020, 01:43:00 PM

BMO Reiterates $10 Price Target On Kinross Gold Following Russian Asset Sale

On April 5th, Kinross Gold (TSX: K) announced the sale of its Russian assets, with...

Saturday, April 9, 2022, 03:03:00 PM

Well Health: Canaccord Reiterates Ratings Following Recent Acquisition

Last week WELL Health Technologies (TSX: WELL) announced their latest acquisition, a majority stake in...

Friday, September 10, 2021, 03:29:00 PM

Well Health: Consensus Price Target Climbs To $11.83 Following MyHealth Acquisition

WELL Health Technologies Corp. (TSX: WELL) this week announced that they would be acquiring MyHealth...

Thursday, June 10, 2021, 11:46:00 AM

Nvidia: BMO Raises Price Target To $750

Nvidia Corp (NASDAQ: NVDA) reported their fiscal third-quarter earnings on May 26th after market close....

Friday, May 28, 2021, 11:36:00 AM